Multimodal Ophthalmic Imaging and Plasma Biomarkers for the Early Detection of Alzheimer's Disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06924359

Acronym

MOIPAD

Enrollment

200

Registered

2025-04-11

Start date

2025-03-19

Completion date

2027-08-31

Last updated

2025-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease (AD)

Brief summary

With the accelerating global aging population, dementia has become a pressing worldwide issue. This project aims to identify specific plasma biomarkers and ocular indicators for the early detection of Alzheimer's disease (AD).

Interventions

DIAGNOSTIC_TESTMultimodal Ophthalmic Imaging and plasma biomarker

Multimodal Ophthalmic Imaging and plasma biomarkers (Aβ42/40, p-tau181, p-tau217, NfL and GFAP）.

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Inclusion criteria

* Male or female participants aged ≥ 50 years; * Participants diagnosed with Alzheimer's Disease (AD), mild cognitive decline (MCI), subjective cognitive decline (SCD), or cognitively normal (CN); * Signed informed consent form

Exclusion criteria

* Presence of other neurological disorders and systemic diseases that may cause cognitive impairment; * Inability to cooperate with cognitive assessments; * Refusal to undergo blood sampling.

Design outcomes

Primary

Measure	Time frame
Differences in Multimodal Ophthalmic Imaging parameter values among groups	Baseline

Secondary

Measure	Time frame
Concentration difference of plasma biomarkers (Aβ42/40, p - tau181, p - tau217, NfL and GFAP） among groups	Baseline

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026